Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future

Babkoff, A.; Zick, A.; Hubert, A.; Tarantino, P.; Grinshpun, A.

doi:10.1016/j.esmogo.2023.100032

Cited by 14Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future

Open access

Babkoff, A., Zick, A., Hubert, A., Tarantino, P., Grinshpun, A.·2024·ESMO Gastrointestinal Oncology

DOI 10.1016/j.esmogo.2023.100032PMC PMC12836600

Open this paper in CoChat — free account Open PDF

Abstract

Colorectal cancer (CRC) constitutes a significant portion of cancer-related deaths in the United States, topping cancer-related mortality among males under 50 years of age. Despite an increase in overall survival throughout the years, the prognosis of metastatic CRC remains poor. In addition to the classic molecular targets in CRC that include epidermal growth factor receptor, BRAF, and vascular endothelial growth factor pathways, human epidermal growth factor receptor 2 (HER2) amplification is an emerging target that has been successfully targeted in advanced CRC, particularly with anti-HER2 monoclonal antibodies and tyrosine kinase inhibitors. With the introduction of potent HER2-directed antibody-drug conjugates, the number of patients who might be eligible for anti-HER2 therapy is expected to increase dramatically as tumors with lower expression of HER2 (termed HER2 low) have shown relevant response rates across several histologies. Yet, several challenges remain to be addressed in this field, including the standardized method to define HER2-low disease and the most efficient payload in this setting, among others. Future studies will help to further characterize HER2-low CRCs, identify additional predictive biomarkers, and assist in the development of better treatments.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.esmogo.2023.100032

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The prevalence of ERBB2-low disease in metastatic colorectal cancer is between 6% and 30%.
“the prevalence of erb-b2 receptor tyrosine kinase 2 (ERBB2)-low disease in mCRC is between 6% and 30%.44”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [44]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2023
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303 · see citing works
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · see citing works
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · see citing works
Colorectal cancer statistics, 2023
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21772 · Cited by 3,907 · see citing works
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · see citing works
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,313 · see citing works
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099 · see citing works
Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836 · see citing works
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824 · see citing works
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M. J., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,764 · see citing works
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279 · see citing works
Entrectinib in Patients with Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1-2 Trials
Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790 · see citing works
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Cercek, A., Lumish, M. A., Sinopoli, J. C., Weiss, J. A., Shia, J., Lamendola-Essel, M. F., Dika, I. H. E., Segal, N. H., Shcherba, M., Sugarman, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201445 · Cited by 1,665 · see citing works
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491 · see citing works
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients with Metastatic Colorectal Cancer Previously Treated with an Oxaliplatin-Based Regimen
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402 · see citing works
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333 · see citing works
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115022 · Cited by 1,257 · see citing works
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,175 · see citing works
Continuation of Bevacizumab after First Progression in Metastatic Colorectal Cancer (ML18147): A Randomised Phase 3 Trial
Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166 · see citing works
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Meric‐Bernstam, F., Makker, V., Oaknin, A., Oh, D., Banerjee, S. N., González-Martı́n, A., Jung, K. H., Lugowska, I. A., Manso, L., Manzano, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.02005 · Cited by 1,090 · see citing works
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016 · see citing works
Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164
Le, D. T., Kim, T. W., Van Cutsem, E., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B., Kavan, P., Yoshino, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02107 · Cited by 1,005 · see citing works
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
Diaz, L. A., Shiu, K., Kim, T., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D. M., García‐Carbonero, R., Benavides, M., Gibbs, P., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00197-8 · Cited by 969 · see citing works
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Hurvitz, S. A., Hegg, R., Chung, W., Im, S., Jacot, W., Ganju, V., Chiu, J. W. Y., Xu, B., Hamilton, E. P., Madhusudan, S., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02420-5 · Cited by 714 · see citing works
Final Results from PRIME: Randomized Phase III Study of Panitumumab with FOLFOX4 for First-Line Treatment of Metastatic Colorectal Cancer
Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu141 · Cited by 606 · see citing works
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Meric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30904-5 · Cited by 573 · see citing works
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
Krop, I. E., Kim, S., González-Martı́n, A., LoRusso, P. M., Ferrero, J.-., Badovinac-Črnjević, T., Hoersch, S., Smitt, M. C., & Wildiers, H. P. M. W. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30313-3 · Cited by 533 · see citing works
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
Koopman, M., Kortman, G. A. M., Mekenkamp, L. J., Ligtenberg, M. J. L., Hoogerbrugge, N., Antonini, N. F., Punt, C. J. A., & van Krieken, J. H. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604867 · Cited by 515 · see citing works
Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution
Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S., & Bardelli, A. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0462 · Cited by 513 · see citing works
Molecular characterization of cancers with NTRK gene fusions
Gatalica, Z., Xiu, J., Swensen, J. J., & Vranić, S. (2018) · Modern Pathology · doi:10.1038/s41379-018-0118-3 · Cited by 491 · see citing works
Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer
Piawah, S., & Venook, A. P. (2019) · Cancer · doi:10.1002/cncr.32163 · Cited by 491 · see citing works
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
Subbiah, V., Wolf, J., Konda, B., Kang, H., Spira, A. I., Weiss, J. M., Takeda, M., Ohe, Y., Khan, S. A., Ohashi, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00541-1 · Cited by 460 · see citing works
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+
Fehrenbacher, L., Cecchini, R. S., Geyer, C. E., Rastogi, P., Costantino, J. P., Atkins, J. N., Crown, J. P., Polikoff, J. A., Boileau, J.-F., Provencher, L., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01455 · Cited by 403 · see citing works
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
André, F., Park, Y. H., Kim, S., Takano, T., Im, S., Borges, G. D. S., Lima, J. P. D. S. N., Aksoy, S., Gregori, J. G., Laurentiis, M. D., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00725-0 · Cited by 395 · see citing works
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
Kopetz, S., Guthrie, K. A., Morris, V. K., Lenz, H., Magliocco, A. M., Maru, D. M., Yan, Y., Lanman, R. B., Manyam, G. C., Hong, D. S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01994 · Cited by 390 · see citing works
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Valtorta, E., Martino, C., Bianchi, A. S., Penault-Llorca, F. M., Viale, G., Risio, M., Rugge, M., Grigioni, W., Bencardino, K. B., Lonardi, S., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.98 · Cited by 317 · see citing works
HER2 testing in gastric cancer: An update
Abrahão‐Machado, L. F., & Scapulatempo‐Neto, C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i19.4619 · Cited by 311 · see citing works
The RET proto-oncogene in human cancers
Jhiang, S. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203857 · Cited by 297 · see citing works
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Tarantino, P., Ricciuti, B., Pradhan, S. M., & Tolaney, S. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00783-w · Cited by 269 · see citing works
Self-citation
Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Gianni, L., Lladó, A., Bianchi, G., Cortés, J., Kellokumpu‐Lehtinen, P., Cameron, D., Miles, D. W., Salvagni, S., Wardley, A. M., Goeminne, J.-C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1661 · Cited by 262 · see citing works
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00150-x · Cited by 259 · see citing works
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology
Bartley, A. N., Washington, M. K., Ventura, C. B., Ismaila, N., Colasacco, C., Benson, A. B., Carrato, A., Gulley, M. L., Jain, D., Kakar, S., et al. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0331-cp · Cited by 254 · see citing works
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial
Nakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01553-w · Cited by 231 · see citing works
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines
Grothey, A. F., Fakih, M., & Tabernero, J. M. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.206 · Cited by 216 · see citing works
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
Ross, J. S., Fakih, M., Ali, S. M., Elvin, J. A., Schrock, A. B., Suh, J. H., Vergilio, J., Ramkissoon, S. H., Severson, E. A., Daniel, S., et al. (2018) · Cancer · doi:10.1002/cncr.31125 · Cited by 214 · see citing works
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Meric‐Bernstam, F., Beeram, M., Hamilton, E. P., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00621-0 · Cited by 200 · see citing works
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
Bianchi, A. S., Lonardi, S., Martino, C., Fenocchio, E., Tosi, F., Ghezzi, S., Leone, F., Bergamo, F., Zagonel, V., Ciardiello, F., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000911 · Cited by 185 · see citing works
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38032-4 · Cited by 178 · see citing works
HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression
Seo, A. N., Kwak, Y., Kim, D., Kang, S., Choe, G., Kim, W. H., & Lee, H. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098528 · Cited by 175 · see citing works
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
Masi, G., Salvatore, L., Boni, L., Loupakis, F., Cremolini, C., Fornaro, L., Schirripa, M., Cupini, S., Barbara, C., Safina, V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv012 · Cited by 175 · see citing works
HER2/neu testing in primary colorectal carcinoma
Heppner, B. I., Behrens, H., Balschun, K., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.483 · Cited by 170 · see citing works
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy
Fumagalli, D., Venet, D., Ignatiadis, M., Azim, H. A., Maetens, M., Rothé, F., Salgado, R., Bradbury, I., Pusztai, L., Harbeck, N., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3824 · Cited by 151 · see citing works
Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis
Nagpal, A., Redvers, R. P., Ling, X., Ayton, S., Fuentes, M., Tavancheh, E., Diala, I., Lalani, A. S., Loi, S., David, S., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1177-1 · Cited by 151 · see citing works
Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies
Vogel, A., Hofheinz, R., Kubicka, S., & Arnold, D. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.007 · Cited by 134 · see citing works
Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer
Raghav, K., Loree, J. M., Morris, J. S., Overman, M. J., Yu, R., Meric-Bernstam, F., Menter, D., Korphaisarn, K., Kee, B., Muranyi, A., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00226 · Cited by 132 · see citing works
Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes
Loupakis, F., Depetris, I., Biason, P., Intini, R., Prete, A. A., Leone, F., Lombardi, P., Filippi, R., Spallanzani, A., Cascinu, S., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0611 · Cited by 111 · see citing works
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
Pietrantonio, F., Nicolantonio, F. D., Schrock, A. B., Lee, J., Morano, F., Fucà, G., Nikolinakos, P. G., Drilon, A. E. D. C., Hechtman, J. F., Christiansen, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy090 · Cited by 108 · see citing works
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer
Strickler, J. H., Yoshino, T., Graham, R. P., Siena, S., & Bekaii‐Saab, T. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.8196 · Cited by 104 · see citing works
HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target
Ahcene Djaballah, S., Daniel, F., Milani, A., Ricagno, G., & Lonardi, S. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351354 · Cited by 95 · see citing works
Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: A systematic review
Presti, D., Dall’Olio, F. G., Besse, B., Ribeiro, J. M., Meglio, A. D., & Soldato, D. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103773 · Cited by 89 · see citing works
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti‐HER2 therapy
Nuciforo, P. G., Thyparambil, S. P., Aura, C. M., Garrido-Castro, A. C., Vilaró, M., Peg, V., Jimenez, J., Vicario, R., Cecchi, F., Hoos, W. A., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.09.002 · Cited by 88 · see citing works
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study
Raghav, K. P. S., Siena, S., Takashima, A., Kato, T., Van Den Eynde, M., Di Bartolomeo, M., Komatsu, Y., Kawakami, H., Peeters, M., Andre, T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.16_suppl.3501 · Cited by 75 · see citing works
The HER2-low revolution in breast oncology: steps forward and emerging challenges
Nicolò, E., Bielo, L. B., Curigliano, G., & Tarantino, P. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231152842 · Cited by 74 · see citing works
Self-citation
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer WithERBB2Amplification orERBB2/3Mutations: Results From the TAPUR Study
Gupta, R., Meric‐Bernstam, F., Rothe, M., Garrett-Mayer, E. S., Mangat, P. K., D’Andre, S. D., Ahn, E. R., O'Lone, R., Halabi, S., Grantham, G. N., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00306 · Cited by 70 · see citing works
Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas
Li, Q., Wang, D., Li, J., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-277 · Cited by 69 · see citing works
Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors
Conlon, N. T., Kooijman, J. J., van Gerwen, S. J. C., Mulder, W. R., Zaman, G. J. R., Diala, I., Eli, L. D., Lalani, A. S., Crown, J. P., & Collins, D. M. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01257-x · Cited by 69 · see citing works
A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
Kim, T. W., Elme, A., Kusić, Z., Park, J. O., Udrea, A. A., Kim, S. Y., Ahn, J. B., Villalobos-Valencia, R., Krishnan, S., Bilic, A., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.309 · Cited by 67 · see citing works
<scp>NTRK</scp> fusion positive colorectal cancer is a unique subset of <scp>CRC</scp> with high <scp>TMB</scp> and microsatellite instability
Wang, H., Li, Z., Ou, Q., Wu, X., Nagasaka, M., Shao, Y., Ou, S. I., & Yang, Y. (2022) · Cancer Medicine · doi:10.1002/cam4.4561 · Cited by 64 · see citing works
International Harmonization of Provisional Diagnostic Criteria for ERBB2 -Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel
Fujii, S., Magliocco, A. M., Kim, J., Okamoto, W., Kim, J. E., Sawada, K., Nakamura, Y., Kopetz, S., Park, W., Tsuchihara, K., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00154 · Cited by 58 · see citing works
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL
Wulfkuhle, J. D., Yau, C. S. F., Wolf, D. M., Vis, D. J., Gallagher, R. I., Swigart, L. B., Hirst, G. L., Voest, E. E., DeMichele, A. M., Hylton, N. M., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00024 · Cited by 51 · see citing works
Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
Wang, X.-Y., Zheng, Z., Sun, Y., et al. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i4.335 · Cited by 40 · see citing works
Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer
Yagisawa, M., Sawada, K., Nakamura, Y., Fujii, S., Yuki, S., Komatsu, Y., Yoshino, T., Sakamoto, N., & Taniguchi, H. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.11.002 · Cited by 36 · see citing works
HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study
Chen, P.-C., Yeh, Y., Chu, C., Su, P., Chiu, P.-H., Lin, B.-W., Chen, S., Lin, P., Lee, C., Chen, H. H. W., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.019 · Cited by 25 · see citing works
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
Cheng, H., Bai, Y., Sikov, W. M., Sinclair, N. F., Bossuyt, V., Abu-Khalaf, M. M., Harris, L. N., & Rimm, D. L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-326 · Cited by 23 · see citing works
Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer
Guo, Y., Guo, X., Wang, S., Chen, X., Shi, J., Wang, J., Wang, K., Klempner, S. J., Wang, W., & Xiao, M. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0356 · Cited by 23 · see citing works
HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients
Tan, R. S. Y. C., Camat, M. D., Ng, M. C. H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy156 · Cited by 18 · see citing works
Abstract 383: Trastuzumab deruxtecan resistance is associated with reduced responsiveness to topoisomerase inhibitors (payload resistance) but no reduction in sensitivity to HER2 tyrosine kinase inhibitors
Nilsson, M. B., Poteete, A., Udagawa, H., Yu, X., He, J., Le, X., & Heymach, J. V. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-383 · Cited by 10 · see citing works
Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.
Sandhu, J. S., Wang, C., & Fakih, M. (2020) · PubMed · doi:10.6004/jnccn.2019.7371 · Cited by 8 · see citing works
Distinct Clinicopathological Features and Prognostic Values of High-, Low-, or Non-Expressing HER2 Status in Colorectal Cancer
Wu, Z., Cheng, Y., Wang, H., Liu, D., Qi, X., Wang, C., Zhang, Y., Zhang, Y., Cai, R., Huo, H., et al. (2023) · Cancers · doi:10.3390/cancers15020554 · Cited by 7 · see citing works
Frequency of Her2-low in colorectal cancer and its relations with the tumor microenvironment
Lang‐Schwarz, C., Vieth, M. W., Dregelies, T., & Sterlacci, W. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154417 · Cited by 5 · see citing works
Clinical and molecular characterization of HER2-low metastatic colorectal cancer.
Babkoff, A., Haran, T. K., Zick, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.16_suppl.e15573 · Cited by 2 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

Current and emerging concepts for systemic treatment of metastatic colorectal cancer
Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335412 · Cited by 39 · see citing works

Authors: Babkoff, A., Zick, A., Hubert, A., Tarantino, P., & Grinshpun, A.
Affiliations: Hebrew University of Jerusalem (IL)
Harvard University (US)
Corresponding author: Grinshpun, A.
ORCID: Zick, A.
Tarantino, P.
Grinshpun, A.
Venue: ESMO Gastrointestinal Oncology
Publisher: Elsevier BV
Published: 2024-03
Volume: 3
Pages: 100032
ISSN: 2949-8198 (ISSN-L)
DOI: 10.1016/j.esmogo.2023.100032
PMC: PMC12836600
OpenAlex: W4391460044
Cited by: 14
References: 81
Citations by year: 2026: 2 · 2025: 7 · 2024: 5
FWCI: 0.75
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: ESMO Gastrointestinal Oncology (publishedVersion, cc-by-nc-nd)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: Gilead Sciences
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: metastatic colorectal cancer, HER2, HER2-targeted therapy, antibody-drug conjugates, HER2 amplification, tyrosine kinase inhibitors, monoclonal antibodies, predictive biomarkers, targeted therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks